PLSE
Pulse Biosciences Inc
53.90$
+6.4%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 39.3% | 27.9% | 63.3% | 77.2% | 85.5% | 63.0% | 54.1% | 67.5% | 79.8% | 76.6% | 90.2% | 86.8% | |
| 39.2% | 25.2% | 7.9% | 6.8% | 72.3% | 16.5% | 30.2% | 52.7% | 78.5% | 75.0% | 89.1% | 84.0% | |
| 39.2% | 25.2% | 62.3% | 76.4% | 84.3% | 60.6% | 49.6% | 52.7% | 78.5% | 75.0% | 89.1% | 84.0% | |
| – | – | – | – | – | – | 0.0% | 0.1% | 0.0% | – | 0.0% | 0.3% | |
| – | – | 0.0% | 0.0% | – | – | 0.0% | 10.7% | 0.0% | – | 0.0% | 0.1% | |
| 1.1% | 2.3% | 1.2% | 5.2% | 3.1% | 18.3% | 6.0% | 20.7% | – | – | – | – | |
| 15.6% | 19.5% | 10.6% | 5.6% | 4.0% | 6.7% | 6.8% | 5.1% | 3.6% | 4.7% | 2.1% | 2.9% | |
| 44.0% | 50.3% | 24.9% | 11.8% | 7.4% | 10.8% | 9.4% | 5.9% | 3.3% | 3.2% | 0.9% | 0.6% | |
| 10.2% | 4.6% | 3.9% | 7.7% | 6.1% | 26.7% | 44.6% | 34.2% | 102.9% | 25.0% | 13.3% | 16.1% | |
| 0.9% | 4.6% | 3.9% | 4.4% | 4.4% | 10.6% | 18.4% | 15.7% | 7.7% | 11.3% | 7.6% | 8.2% | |
| – | – | – | – | – | – | 1.3% | 2.2% | 2.3% | 1.8% | 1.0% | 1.6% | |
| 0.2% | 1.8% | 1.0% | 1.6% | 1.8% | 4.7% | 4.2% | 5.4% | 2.0% | 3.1% | 1.3% | 2.9% | |
| – | – | 0.0% | 0.0% | – | – | – | – | 83.5% | – | – | – | |
| 89.8% | 95.4% | 96.1% | 92.3% | 93.9% | 73.3% | 55.4% | 65.8% | -2.9% | 75.0% | 86.7% | 83.9% | |
| -1.5% | -21.6% | -47.9% | -76.6% | -107.2% | -292.7% | -417.8% | -435.4% | -378.4% | -569.6% | -294.8% | -482.0% | |
| 14.0% | 52.8% | 41.8% | 29.6% | 24.2% | 49.5% | 56.3% | 51.5% | 43.6% | 81.2% | 44.1% | 70.1% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.